Could plasma based therapies still be considered in selected cases with atypical hemolytic uremic syndrome?

Creative Commons License

ÖZLÜ S. G., GÜLHAN B., Aydog O., Atayar E., Delibas A., Parmaksiz G., ...More

TURKISH JOURNAL OF PEDIATRICS, vol.63, no.6, pp.986-993, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 63 Issue: 6
  • Publication Date: 2021
  • Doi Number: 10.24953/turkjped.2021.06.006
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.986-993
  • Keywords: atypical hemolytic uremic syndrome, treatment, plasma infusion, plasma exchange, outcome, CLINICAL CHARACTERISTICS, COMPLEMENT, MUTATIONS, ECULIZUMAB, MANAGEMENT, IMPACT, MICROANGIOPATHY, AHUS
  • Hacettepe University Affiliated: Yes


Background. Atypical hemolytic uremic syndrome (aHUS) occurs due to defective regulation of the alternative complement pathway (ACP) on vascular endothelial cells. Plasma based therapy (PT) was the mainstay of the treatment for aHUS for many years until the introduction of therapies targeting blockage of the complement system. The aim of this study was to evaluate patients with aHUS who had been treated with plasma based therapies alone.